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Abstract Estrogen and estrogen receptors are known to
play important roles in the pathophysiology of pelvic organ
prolapse (POP). We investigated whether estrogen receptor
α (ERα) gene polymorphisms were associated with POP
risk by conducting a case-control association study in 88
women with POP and 153 women without POP. Genotypes
of the ERα (ESR1) gene polymorphisms (rs17847075,
rs2207647, rs2234693, rs3798577, and rs2228480) were
determined by polymerase chain reaction, followed by
restriction fragment length polymorphism analysis. There
was significant difference between women with and those
without POP in the distribution of the ESR1 rs2228480
genotypes evaluated. By using multivariable logistic re-
gression, age and ESR1 rs2228480 genotype GA were
significantly associated with POP risk. Although the sample
size of women with POP studied is small, the present study
shows that ERα genotype may be associated with POP risk.
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polymorphism . Genotype
Abbreviations
POP pelvic organ prolapse
ER estrogen receptor
ERα estrogen receptor α
ESR1 estrogen receptor α
SNPs single nucleotide polymorphisms
ICS International Continence Society
PCR polymerase chain reaction
RFLP restriction fragment length polymorphism
Introduction
Pelvic organ prolapse (POP) is a common gynecological
problem [1]. As life expectancy increases, significantly
greater number of women will present with POP requiring
surgical intervention. Currently, the lifetime risk of under-
going prolapse or continence surgery in the USA is 1 in 11,
and up to 30% of patients will require repeat prolapse
surgery [2]. Although the pathophysiology of POP is still
not completely understood, genetic factors and environ-
mental factors are thought to be involved [1].
Estrogen deficiency, collagen abnormality, vaginal parity,
and aging are recognized to be risk factors associated with
POP [3–5], but no study has been able to differentiate
Int Urogynecol J (2008) 19:1159–1163
DOI 10.1007/s00192-008-0603-1
H.-Y. Chen
Department of Obstetrics and Gynecology,
China Medical University Hospital, School of Chinese Medicine,
College of Chinese Medicine, China Medical University,
Taichung, Taiwan
W.-Y. Lin : F.-J. Tsai (*)
Department of Medical Genetics,
China Medical University Hospital, College of Chinese Medicine,
China Medical University,
No. 2 Yu-Der Road,
Taichung 404, Taiwan
e-mail: d0704@hpd.cmuh.org.tw
W.-C. Chen
Department of Urology, China Medical University Hospital,
Institute of Integrated Medicine, College of Chinese Medicine,
China Medical University,
Taichung, Taiwan
Y.-W. Chung
College of Life Science, National Chung Hsing University,
Taichung, Taiwan
C.-H. Tsai
Asia University,
Taichung, Taiwan
between estrogen effects and aging effects with regard to
the risk for POP. Estrogen exerts its effects by interacting
with specific estrogen receptors (ERs), the ERα (ESR1)
and ERβ (ESR2) [6]. The former isoform is a ligand-
activated transcription factor composed of several important
domains for hormone binding, DNA binding, and activa-
tion of transcription [7]. ERα is an important mediator in
signal transduction pathway [7]. The ERα gene is greater
than 140 kb, contains eight exons, and is located on
chromosome 6q25 [8].
The ability to accurately identify individuals at increased
risk for developing POP from a genetic screen would be
revolutionary and enormously useful in order to avoid a critical
inciting events such as vaginal birth [9]. Single nucleotide
polymorphisms (SNPs) are used as a tool for mapping genes
responsible for the disease [10] and might be a suitable
method for studying disease genes responsible for POP.
The concentrations of estrogen and ER of women who
had POP before menopause were lower than those of the
control group [11]. The ERα expression was higher in both
postmenopausal and premenopausal POP patients than the
control groups [12]. Our hypothesis is that genetic
variations in the ERα gene might alter the expression of
the gene and put women at the risk of POP. In the present
study, we investigated a total of five polymorphisms in the
ERα gene: ESR1 rs17847075 (exon 1 C/T), ESR1
rs2207647 (exon 1 G/A), ESR1 rs2234693 (intron 1 T/C),
ESR1 rs3798577 (exon 8 C/T), and ESR1 rs2228480 (exon
8 G/A) [13–17]. We evaluated the correlations between
these polymorphisms and POP risk.
Materials and methods
Study participants
A total of 88 women with POP and 153 women without
POP were recruited. Women who were amenorrheic for
1 year or more were considered menopausal. None of the
menopausal women in this study had received hormone
replacement therapy. The premenopausal women were
submitted to blood drawn between days 2 and 5 of the
menstrual cycle (proliferative phase) [11]. All subjects in a
45° semiupright position with an empty bladder in a
birthing chair were examined during maximum Valsalva
maneuver for staging of POP according to the criteria of the
International Continence Society [18, 19]. All examinations
were performed by a senior gynecologist. The study group
(POP group) had POP stage 2 or higher and control group
(non-POP group) had POP stage 1 or without any signs of
POP. This study was approved by our institutional review
board, and written informed consent was obtained from all
of the women who participated in this study.
Polymerase chain reaction and typing for ERα gene
polymorphisms
The genomic DNA was prepared from peripheral blood
using a DNA Extractor WB kit (Wako, Japan). Polymerase
chain reactions (PCRs) were carried out in a total volume of
50 µl, containing genomic DNA, 2–6 pmol of each primer,
1X Taq polymerase buffer (1.5 mM MgCl2), and 0.25 units
of AmpliTaq DNA polymerase (Applied Biosystems,
Foster City, CA, USA). The primer for the ESR1
rs17847075 (exon 1 C/T), ESR1 rs2207647 (exon 1 G/A),
ESR1 rs2234693 (intron 1 T/C), ESR1 rs3798577 (exon
8 C/T), and ESR1 rs2228480 (exon 8 G/A) gene poly-
morphisms are listed in Table 1 [13–17]. PCR amplification
was performed in a programmable thermal cycle GeneAmp
PCR System 2400 (Applied Biosystems, Foster City, CA,
USA). The cycling conditions are given in Table 1.
The ESR1 rs17847075 (exon 1 C/T) polymorphism was
analyzed by PCR amplification, followed by restriction
fragment length polymorphism (RFLP) analysis using Msp
I (New England Biolabs, Beverly, MA, USA) digestion.
The “C” allele of the ESR1 rs17847075 showed up as 198,
Table 1 Sequences of primers used for estrogen receptor alpha genotyping
Polymorphism site Primer sets Annealing temperature
(°C)
Digestion Allele size
(bp)
ESR1 rs17847075 (exon 1 C/T) 5′-ATGCGCTGCGTCGCCTCTAA-3′ 62 Msp I, 37°C C 198+121+90+53+18
5′-CTGCAGGAAAGGCGACAGCT-3′ T 288+121+53+18
ESR1 rs2207647 (exon 1 G/A) 5′-GCTTGCTGCTGTCCAGGTACA-3′ 62 Msp I, 37°C A 145
5′-ATGACCATGACCCTCCACACC-3′ G 114+31
ESR1 rs2234693 (intron 1 T/C) 5′-AGAGGAGTTTTGAATATTGAAG-3′ 55 Pvu II, 37°C C 297
5′-TAGCTGGTTTCTAATAGACTTA-3′ T 165+132
ESR1 rs3798577 (exon 8 C/T) 5′-GGTGAACTGTTCACTGTGGT-3′ 55 AlwN I, 37°C C 106+50
5′-TCTGCCCTACTTTCCCTCTT-3′ T 156
ESR1 rs2228480 (exon 8 G/A) 5′-GCTCTACTTCATCGCATTCC-3 58 Btg I, 37°C A 238
5′-CCACTAAGAACTGAGCAAGC-3′ G 174+64
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121, 90, 53, and 18 bp on agarose electrophoresis. The “T”
allele of the ESR1 rs17847075 presented fragments of 288,
121, 53, and 18 bp. The ESR1 rs2207647 (exon 1 G/A)
gene polymorphism was determined by PCR amplification,
followed by RFLP analysis using Msp I (New England
Biolabs, Beverly, MA, USA) digestion. The “G” allele of the
ESR1 rs2207647 was 114 and 31 bp, and the “A” allele of
the ESR1 rs2207647 was 145 bp on agarose electrophoresis.
The ESR1 rs2234693 (intron 1 T/C) gene polymorphism
was analyzed by PCR amplification, followed by RFLP
analysis using Pvu II (New England Biolabs, Beverly,
MA, USA) digestion. The “C” allele of the ESR1
rs2234693 showed up as 297 bp, and the “T” allele of
the ESR1 rs2234693 was 165 and 132 bp on agarose
electrophoresis. The ESR1 rs3798577 (exon 8 C/T) gene
polymorphism was analyzed by PCR amplification,
followed by RFLP analysis using AlwN I (New England
Biolabs, Beverly, MA, USA) digestion. The “C” allele of
the ESR1 rs3798577 showed up as 106 and 50 bp, and the
“T” allele of the ESR1 rs3798577 was 156 bp on agarose
electrophoresis. The ESR1 rs2228480 (exon 8 G/A) gene
polymorphism was analyzed by PCR amplification, fol-
lowed by RFLP analysis using Btg I (New England Biolabs,
Beverly, MA, USA) digestion. The “A” allele of the ESR1
rs2228480 showed up as 238 bp on agarose electrophoresis.
The “G” allele of the ESR1 rs2228480 was 174 and 64 bp.
Statistical analysis
Mann–Whitney test (Wilcoxon rank–sum test) and chi-
square test were used for nonparametric ordinal and
nonparametric categorical variables, respectively. When
the assumption of the chi-square test was violated (i.e.,
when more than one cell had an expected count of less than
1, or more than 20% of the cells had an expected count of
less than 5), Fisher’s exact test was used. Genotype
frequencies were tested for Hardy–Weinberg equilibrium
as a check against genotyping assay problem. A logistic
regression model and odds ratios (OR; with 95% confi-
dence intervals (CI)) were used to assess the independent
prognostic value of the variables associated with POP risk.
All statistical tests were two-sided. P value less than 0.05
was considered statistically significant. All calculations
were performed by the Statistical Package for Social
Sciences (SPSS for Windows, release 8.0, SPSS Inc.,
Chicago, IL, USA).
Results
The prevalence of each genotype of the ESR1 rs17847075
(exon 1 C/T) polymorphism was 14.5% CC, 45.7% CT, and
39.8% TT; that of the ESR1 rs2207647 (exon 1 G/A)
polymorphism was 13.7% GG, 46.1% GA, and 40.2% AA.
The prevalence of each genotype of the ESR1 rs2234693
(intron 1 T/C) polymorphism was 39% TT, 46.1% TC, and
14.9% CC; that of the ESR1 rs3798577 (exon 8 C/T)
polymorphism was 19.1% CC, 44.8% CT, and 36.1% TT.
Finally, the prevalence of each genotype of the ESR1
rs2228480 (exon 8 G/A) polymorphism was 61% GG,
35.3% GA, and 3.7% AA. The five genotype distributions
were in Hardy–Weinberg equilibrium.
We analyzed the influence of five factors on POP: age,
parity, body mass index (BMI), menopausal status, and
ERα gene polymorphisms (ESR1 rs17847075 (exon 1 C/T),
ESR1 rs2207647 (exon 1 G/A), ESR1 rs2234693 (intron 1
T/C), ESR1 rs3798577 (exon 8 C/T), and ESR1 rs2228480
(exon 8 G/A); Table 2). Of these, older age, increased parity,
greater BMI, menopausal status, and incidence of ESR1
rs2228480 genotype GA were found to be significantly
associated with POP risk.
Univariable logistic regression revealed that older age,
increased parity, greater BMI, menopausal status, and
incidence of ESR1 rs2228480 genotype GA were signifi-
cantly associated with POP risk. The ESR1 rs2228480
genotype AA appeared to be a “protective” genotype for
POP (OR 0.38, 95% CI 0.05–3.19, P=0.373). The ESR1
rs2228480 genotype GA appeared to be a significant
“at-risk” genotype for POP (OR 1.87, 95% CI 1.04–3.38,
P=0.038). In view of univariable analyses, we next
performed a multivariable logistic regression analysis
including all significant or border-line significance risk
factors which were found in the univariable analyses. In the
model, the final result showed that older age and incidence
of ESR1 rs2228480 genotype GA were significantly
associated with POP risk (Table 3). That is, older age and
incidence of ESR1 rs2228480 genotype GA were signifi-
cant “at-risk” factors for POP (age, OR 1.05, 95% CI 1.01–
1.10, P=0.002; ESR1 rs2228480 genotype GA, OR 2.05,
95% CI 1.05–4.02, P=0.036). Others thought to be
potential risk factors, such as parity, BMI, and menopausal
status found in the univariable analyses, were not shown to
be significant in the multivariable analysis. Their effects
seem to be explained by genetic factor and age.
Discussion
To test our hypothesis that sequence variations in the ERα
gene are associated with POP risk, we analyzed the exon 1,
intron 1, and exon 8 region of the gene in 88 women with
POP and 153 women without POP. To our knowledge, this
is the first study to evaluate the association between
sequence variations in the ERα gene and POP risk. The
genotype frequency estimation analysis revealed that the
ESR1 rs2228480 genotype GA was more prevalent in
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women with POP (46.6%) than in women without POP
(28.8%). The P value of the chi-square test was about 1.5%
with a power greater than 74%. The ESR1 rs2228480
genotype GA, therefore, seems to be a risk factor for
developing POP.
Many clinicians are confronted by increased numbers of
patients requesting elective cesarean sections to preserve
the pelvic floor and perineum [20]; therefore, the ability to
accurately identify women at risk for POP is needed.
Multiparity, obstetric trauma, chronic increased intra-
abdominal pressure, aging, estrogen deficiency, and genetic
factors are well-known risk factors for developing POP [1,
21–22]. In this study, we assessed the relationship among
clinical features, genetic factors, and POP. Our results show
that age and ESR1 rs2228480 genotype GA are significant
“at-risk” factors for developing POP. This result suggests
that genetically susceptible individuals will experience
POP.
Table 3 Logistic regression of factors associated with pelvic organ prolapse risk
Covariate Univariate analysis Multivariate analysis
Odds ratio (95% CI) P value Odds ratio (95% CI) P value
Age (years) 1.09 (1.06–1.12) <0.001 1.05 (1.01–1.10) 0.002
Parity 1.74 (1.40–2.16) <0.001 1.25 (0.96–1.62) 0.100
Body mass index (kg/m2) 1.09 (1.01–1.93) 0.033 1.08 (0.97–1.20) 0.149
Menopause 5.48 (3.92–10.27) <0.001 1.68 (0.68–4.13) 0.261
ESR1 rs2228480 (exon 8 G/A)
GG 1.0 1.0
GA 1.87 (1.04–3.38) 0.038 2.05 (1.05–4.02) 0.036
AA 0.38 (0.05–3.19) 0.373 0.52 (0.05–5.03) 0.571
CI Confidence interval
Table 2 Analysis of clinical features and estrogen receptor alpha gene polymorphisms of 241 women with and without pelvic organ prolapse
Variables Non-POP (n=153) POP (n=88) P value
No. (%) No. (%)
Age (years) 50.3±9.7 61.1±12.3 <0.001a
Parity (median) 3 (0–7) 4 (1–8) <0.001a
Body mass index (kg/m2) 23.3±3.1 24.2±3.2 0.018a
Menopause 69 (45.1) 72 (81.8) < 0.001b
ESR1 rs17847075 (exon 1 C/T)
CC 23 (15) 12 (13.6) 0.864b
CT 71 (46.4) 39 (44.3)
TT 59 (38.6) 37 (42)
ESR1 rs2207647 (exon1 G/A)
GG 21 (13.7) 12 (13.6) 0.982b
GA 71 (46.4) 40 (45.5)
AA 61 (39.9) 36 (40.9)
ESR1 rs2234693 (intron 1 T/C)
TT 58 (37.9) 36 (40.9) 0.828b
TC 73 (47.7) 38 (43.2)
CC 22 (14.4) 14 (15.9)
ESR1 rs3798577 (exon 8 C/T)
CC 27 (17.6) 19 (31.6) 0.761b
CT 70 (45.8) 38 (43.2)
TT 56 (36.6) 31 (35.2)
ESR1 rs2228480 (exon 8 G/A)
GG 102 (66.6) 45 (51.1) 0.015b
GA 44 (28.8) 41 (46.6)
AA 7 (4.6) 2 (2.3)
Values are mean±standard deviation.
aMann–Whitney test
b Chi-square test
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Premenopausal women had lower collagen concentration
in the pelvic floor in comparison to controls. This
difference is not registered after menopause indicating a
possible disturbed extracellular matrix in the premenopausal
POP [23]. The present study shows that ERα genotype may
be associated with POP. The statistical analyses of the
clinical features of the recruited patients in case of
menopausal status are not clear. In the non-POP group,
only half of the patients are menopausal; in the POP group,
there are 80%. The genotype frequency estimation analysis
revealed that the ESR1 rs2228480 genotype GA was more
prevalent in postmenopausal women with POP (47.2%)
than in postmenopausal women without POP (29%; P=
0.047). Our sample size was relatively small, and our data
were subjected to a number of uncorrected tests. Therefore,
our positive results may represent false-positive findings. A
large cohort size is needed to confirm this association. It
seems better to avoid such kind of “mix,” instead using
matched cases for investigation. Further characterizing
studies of ERα genotype and their relationship with POP
need to be conducted. Besides transcriptional regulation,
posttranslational modification of the ERα gene may play a
role in the bioactivity of the ERα.
In conclusion, our results show that ERα genotype may
be associated with POP risk. Genetic variations in the
estrogen receptor alpha gene might play a role in
susceptibility in POP. Further study of other SNPs using
additional genetic markers might provide new information
about the genetic background of POP pathogenesis.
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